

Use of a Three-Dimensional Microarray System for Detection of Levofloxacin Resistance and the *mecA* Gene in *Staphylococcus aureus*

Tomonori Nagaoka,^{1,2} Toshinobu Horii,^{1*} Takatomo Satoh,² Tomoko Ito,² Akio Monji,³
 Akihiro Takeshita,¹ and Masato Maekawa¹

Department of Laboratory Medicine, Hamamatsu University School of Medicine, 1-20-1 Handa-yama, Hamamatsu 431-3192, Japan¹; Biomedical Business Incubation Division, OLYMPUS Corporation, Hachioji 192-8512, Japan²; and Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan³

Received 6 January 2005/Returned for modification 3 February 2005/Accepted 19 July 2005

We evaluated a novel three-dimensional microarray (PamChip microarray) system to detect the presence of levofloxacin-related resistance mutations and the *mecA* gene. The results were compared to those obtained for 27 *Staphylococcus aureus* isolates by conventional DNA sequencing or PCR methods. Hybridization and fluorescence detection were performed using an FD10 system designed for PamChip microarray under conditions optimized for each target/probe on the array. In dilution series analysis using multiplex PCR samples, the sensitivity of the microarray was about 10 times greater than that of conventional PCR methods. A high level of data reproducibility was also confirmed in those analyses. Various point mutations in quinolone resistance-determining regions detected by our system corresponded perfectly to the results obtained by conventional DNA sequencing. The results of the *mecA* gene detection using our system also corresponded to the PCR method; that is, signal/band was detected in all isolates of methicillin-resistant *S. aureus*, and no signal/band was detected in any isolate of methicillin-susceptible *S. aureus*. In conclusion, our novel three-dimensional microarray system provided rapid, specific, easy, and reproducible results for the simultaneous detection of levofloxacin resistance and the *mecA* gene in *S. aureus*.

Effective antibiotic therapy for infections caused by *Staphylococcus aureus* can be difficult because of resistance to various antibiotics, including β -lactams, aminoglycosides, and fluoroquinolones (1, 11, 12, 15). β -Lactam and fluoroquinolone resistance is generally detected by established conventional susceptibility testing. The conventional susceptibility testing method is not complex or time consuming in terms of hands-on time, although it takes 2 or 3 days for the result. Methicillin resistance is derived from acquisition of the *mecA* gene encoding penicillin-binding protein 2' by methicillin-resistant *S. aureus* (MRSA) (18, 19, 25, 29). The presence of the *mecA* gene is easily detected by the conventional PCR method (18, 19, 25). To remove PCR sizing artifacts, however, a more specific method, such as either hybridization or restriction digestion following PCR, is required. Fluoroquinolone resistance is conferred mainly by codon mutations in the quinolone resistance-determining regions (QRDRs) of the *gyrA* and *gyrB* (*gyrAB*) genes encoding subunits of DNA gyrase and of the *grlA* and *grlB* (*grlAB*) genes encoding subunits of DNA topoisomerase IV (6, 7, 11, 13). Point mutations in the QRDRs of the *gyrA*, *gyrB*, *grlA*, and *grlB* genes have been linked to the degree of fluoroquinolone resistance in MRSA (11, 22, 23). These point mutations are usually determined by conventional DNA sequencing as a gold standard method. In clinical laboratories, however, the ability to genetically determine fluoroquinolone

resistance is limited by the complex and time-consuming nature of conventional DNA sequencing.

Recently, some new genotyping methods, such as the microarray technique, degenerate high-performance liquid chromatography, real-time PCR, TaqMan assay, and Invader assay, have been developed (2, 5, 8, 14, 32). The DNA microarray technique could have the ability to simultaneously analyze multiple-point mutations or deleted and/or inserted regions. In particular, the newly developed PamChip microarray (PamGene International, Hertogenbosch, The Netherlands) is a unique three-dimensional (3-D) flowthrough platform for kinetic hybridization reactions (30). Unlike general microarrays that employ a two-dimensional (2-D) substrate such as a glass slide, the PamChip microarray has long branching capillaries that bind probe DNA molecules onto a solid 3-D structure substrate (Fig. 1). The reactive surface of this substrate is several hundredfold larger than that of a 2-D substrate. A hybridization and image capture station, FD10 (Olympus Corporation, Tokyo, Japan), ensures an optimal solution-driven reaction on the PamChip microarray by repeated pumping of the sample (9, 17). In combination, the PamChip microarray and the FD10 system carry out semiautomatic, rapid, and specific hybridization reactions (17). Furthermore, the system is designed for the simultaneous analysis of four arrays.

Kinetic hybridization is required for the simultaneous detection of multiple-point mutations and the presence of DNA sequences within a single microarray, because each target/probe has a different melting temperature (T_m). One set of conditions for an array containing multiple targets/probes may not be optimal for each target/probe on the array. One main advantage of the PamChip microarray system compared to

* Corresponding author. Mailing address: Department of Laboratory Medicine, Hamamatsu University School of Medicine, 1-20-1 Handa-yama, Hamamatsu 431-3192, Japan. Phone: 81-53-435-2788. Fax: 81-53-435-2794. E-mail: horiihm@hama-med.ac.jp.



FIG. 1. Configuration of PamChip microarray. Representative magnified views of the upper phase (a) and a cross section of the flowthrough 3-D-structure substrate (b) and a magnified view of the array and an outward view of the PamChip microarray (c) are shown.

other microarray formats, including 2-D arrays, is the flexibility for the optimization of hybridization conditions for each target/probe on the array using changes in specific reagents or in temperature.

In this study, to confirm the utility of the PamChip microarray system in the detection of levofloxacin resistance and the *mecA* gene, we compared the results obtained by the microarray method with those obtained by conventional DNA sequencing and PCR methods. On the microarray, the multiple-point mutations in the QRDRs were detected with sequencing by hybridization (SBH), and the presence of the *mecA* gene was detected with reverse dot blot hybridization (RDBH), in *S. aureus* isolates. The applicability of the system for future diagnosis is also discussed.

MATERIALS AND METHODS

Bacterial strains, media, and culture conditions. Twenty-four levofloxacin-resistant MRSA isolates (MICs of >4 $\mu\text{g/ml}$) and three methicillin-susceptible *S. aureus* (MSSA) isolates were used in this study (see Table 3). The MICs for all MRSA isolates were determined by an agar dilution method described by CLSI (formerly NCCLS), which was used in our previous report (11). The clinical isolates were obtained from different patients in Hamamatsu city hospitals between 2001 and 2004. Bacteria were stored at -70°C in heart infusion broth (Nissui Pharmaceutical, Tokyo, Japan) containing 20% glycerol. Subsequently, bacteria were inoculated on heart infusion agar plates (Nissui Pharmaceutical) and incubated at 37°C overnight.

DNA techniques. Genomic DNA of *S. aureus* was extracted according to a method previously reported (10, 21). Extracted DNA was applied to a 0.2-ml PCR tube to perform PCR. Primers used for the amplification of the QRDRs of the *gyrA*, *gyrB*, *grlA*, and *grlB* genes were prepared as previously reported (11). PCR was performed with *Ex Taq* DNA polymerase (Takara Biomedicals, Ohtsu, Japan). To determine point mutations in the QRDRs of the *gyrAB* and *grLAB* genes by conventional DNA sequencing, amplified products of all isolates were directly sequenced with a BigDye Terminator cycle-sequencing FS ready reaction kit and an ABI PRISM 310 genetic analyzer (Applied Biosystems, Foster City, CA).

Conventional PCR for *mecA* gene detection was performed under conditions the same as those for the multiplex PCR mentioned below, excluding primers for *gyrAB* and *grLAB* gene amplifications. Amplified fragments were checked by electrophoresis using a LabChip 7500 assay kit and an Agilent 2100 bioanalyzer (Agilent Technologies, Palo Alto, CA).

Multiplex PCR. To detect point mutations in the QRDRs of the *gyrAB* and *grLAB* genes and the presence of the *mecA* gene on the microarray, targets were amplified simultaneously by multiplex PCR. Sets of multiplex PCR primers are shown in Table 1. For amplifications of *gyrAB* and *grLAB* genes, multiplex primer sets were designed from DNA sequences in public databases by using the primer analysis software OLIGO version 6 (Molecular Biology Insights, Cascade, CO). For all PCR primers, T_m values were adjusted within the range of 54.7 to 60.5°C , and the GC content ranged from 30% to 55%. Multiplex PCR was performed in a solution containing 0.5 μM of each 5'-fluorescein isothiocyanate-labeled primer (Sigma-Aldrich Japan, Tokyo, Japan), 200 μM deoxynucleoside triphosphate, and 2.5 U of *Ex Taq* DNA polymerase for 40 cycles of 94°C for 1 min, 50°C for 2 min, and 72°C for 1 min. To establish the validity of the multiplex PCR method, amplified fragments were checked using a LabChip 7500 kit and an Agilent 2100 bioanalyzer. After the multiplex PCR condition was established, PCR products were hybridized directly on the microarray.

Probe design. Eighteen common genotypes in the QRDRs for our microarray analysis were selected based on our previous report and those of others (4, 11, 14, 26, 27, 28). Sense and antisense oligonucleotide probes from 20 to 26 bases were used to determine specific point mutations in the QRDRs of the *gyrAB* and *grLAB* genes and to detect *mecA*-specific DNA sequences (Table 2). Sets of perfect-match probes for the wild type (Wt) and for specific mutants were prepared to determine the genotype with respect to each point mutation. The specific point mutations reported previously were at codons 84, 85, and 88 in *gyrA*; at codons 47, 79, 80, and 84 in *grlA*; and at codon 451 in *grlB*. Thirty-six probes were used for SBH analysis, the T_m values for these probes were adjusted within the range of 52 to 56°C , and the GC content was 30% to 50%. Twelve sense and antisense probes were designed to detect a single-point mutation at a single codon, with 24 probes for double-point mutations at a single or tandem codon. These point

TABLE 1. Multiplex PCR primers

Target gene	Primer	Sequence (5'→3')	Length (base)	T_m (°C)	GC %	Size (bp)
<i>grlAB</i>	grl-1	AACGAAATCTAAATTGGGTA	20	55.3	30	1,457
	grl-2	GGAAATCTTGATGGCAATAC	20	58.4	40	
<i>gyrAB</i>	gyr-1	TGAAGTAACACGTCGTAAAT	20	54.7	35	1,255
	gyr-2	AGGTAAGACTGACGGCTCTC	20	60.0	55	
<i>mecA</i> ^a	GMECAR-1	ACTGCTATCCACCCTCAAAC	20	60.5	50	163
	GMECAR-2	CTGGTGAAGTTGTAATCTGG	20	57.1	45	

^a Primers for amplification of the *mecA* gene were previously described by Mehrotra et al. (18).

mutations were presented in the centers of the probe sequences. The point mutations, which involved an 8-base interval between codons 85 and 88 in *gyrA* and a 10-base interval between codons 80 and 84 in *grlA*, were detected using specific probes. To detect the *mecA* sequence, probes for RDBH were derived from 26-base sequences in the *mecA* gene. These 38 probes were spotted onto the PamChip microarray according to the layout shown in Fig. 2. The microarray was designed to determine eight point mutation sites, including eighteen genotypes in the QRDRs, and to detect the DNA sequence of the *mecA* gene simultaneously.

Microarray analysis. To confirm the sensitivity and reproducibility of the assay using the microarray system, multiplex PCR products amplified from two MRSA isolates (HU2000-62S and -64) were used as hybridization samples in a dilution series. The dilution concentrations were 1/10, 1/50, and 1/100. Those were prepared by using a LabChip 7500 kit and an Agilent 2100 bioanalyzer.

Hybridization and fluorescence detection were performed automatically by the FD10 system. Before hybridization, each array (test site) of the microarray was washed with 0.1% Tween 20 for a single pumping cycle. Multiple amplified PCR products were denatured for 3 min at 94°C and cooled on ice. The denatured

TABLE 2. The 38 probes for PamChip microarray

Probe no.	Sequence (5'→3') ^a	Length	T_m (°C)	GC %	Strand ^b	Mutation ^c	Gene
1	GCGATATTACCAATTACGTGG	20	54	45	S	P451(Wt)	<i>grlB</i>
2	GCGATATTATCATTACGTGG	20	52	40	S	P451S	<i>grlB</i>
3	CCACGTAATGGTAATATCGC	20	54	45	AS	P451(Wt)	<i>grlB</i>
4	CCACGTAATGATAATATCGC	20	52	40	AS	P451S	<i>grlB</i>
5	GTCGTATTTTATACGCAATGTATTC	25	53	32	S	Y47(Wt)	<i>grlA</i>
6	GTCGTATTTTATATGCAATGTATTC	25	52	28	S	Y47Y(Si)	<i>grlA</i>
7	GAATACATTGCGTATAAAAATACGAC	25	53	32	AS	Y47(Wt)	<i>grlA</i>
8	GAATACATTGCATATAAAAATACGAC	25	52	28	AS	Y47Y(Si)	<i>grlA</i>
9	TCAGTGACGAAAGCAATGGT	20	54	45	S	E84(Wt)	<i>grlA</i>
10	TCAGTGACAAAGCAATGGT	20	52	40	S	E84K	<i>grlA</i>
11	ACCATTGCTTTCGTACACTGA	20	54	45	AS	E84(Wt)	<i>grlA</i>
12	ACCATTGCTTTGTACACTGA	20	52	40	AS	E84K	<i>grlA</i>
13	ACATGGAGACTCCTCAGTGT	20	56	50	S	D79(Wt)S80(Wt)	<i>grlA</i>
14	ACATGGAGACTACTCAGTGT	20	54	45	S	D79(Wt)S80Y	<i>grlA</i>
15	ACATGGAGACTTCTCAGTGT	20	54	45	S	D79(Wt)S80F	<i>grlA</i>
16	ACATGGAGTCTCCTCAGTGT	20	56	50	S	D79VS80(Wt)	<i>grlA</i>
17	ACATGGAGTCTACTCAGTGT	20	54	45	S	D79VS80Y	<i>grlA</i>
18	ACATGGAGTCTTCTCAGTGT	20	54	45	S	D79VS80F	<i>grlA</i>
19	ACACTGAGGAGTCTCCATGT	20	56	50	AS	D79(Wt)S80(Wt)	<i>grlA</i>
20	ACACTGAGTAGTCTCCATGT	20	54	45	AS	D79(Wt)S80Y	<i>grlA</i>
21	ACACTGAGAAAGTCTCCATGT	20	54	45	AS	D79(Wt)S80F	<i>grlA</i>
22	ACACTGAGGAGACTCCATGT	20	56	50	AS	D79VS80(Wt)	<i>grlA</i>
23	ACACTGAGTAGTACTCCATGT	20	54	45	AS	D79VS80Y	<i>grlA</i>
24	ACACTGAGAAGACTCCATGT	20	54	45	AS	D79VS80F	<i>grlA</i>
25	CTATTTATGAAGCAATGGTACG	22	52	36	S	E88K(Wt)	<i>gyrA</i>
26	CTATTTATAACGCAATGGTACG	22	52	36	S	E88K	<i>gyrA</i>
27	CGTACCATTGCTTCATAAATAG	22	52	36	AS	E88K(Wt)	<i>gyrA</i>
28	CGTACCATTGCGTTATAAATAG	22	52	36	AS	E88K	<i>gyrA</i>
29	CTCATGGTGACTCATCTATTTAT	23	53	34	S	S84(Wt)S85(Wt)	<i>gyrA</i>
30	CTCATGGTGACTCACCTATTTAT	23	55	39	S	S84(Wt)S85P	<i>gyrA</i>
31	CTCATGGTGACTTATCTATTTAT	23	51	30	S	S84LS85(Wt)	<i>gyrA</i>
32	CTCATGGTGACTTACCTATTTAT	23	53	34	S	S84LS85P	<i>gyrA</i>
33	ATAAATAGATGAGTCACCATGAG	23	53	34	AS	S84(Wt)S85(Wt)	<i>gyrA</i>
34	ATAAATAGGTGAGTCACCATGAG	23	55	39	AS	S84(Wt)S85P	<i>gyrA</i>
35	ATAAATAGATAAGTCACCATGAG	23	51	30	AS	S84LS85(Wt)	<i>gyrA</i>
36	ATAAATAGGTAAGTCACCATGAG	23	53	34	AS	S84LS85P	<i>gyrA</i>
37	GTATGGCATGAGTAACGAAGAATATA	26	55	34	S		<i>mecA</i>
38	TATATTCTTCGTTACTCATGCCATAC	26	55	34	AS		<i>mecA</i>

^a DNA sequences of the codons with point mutations are underlined.

^b S, sense strand; AS, antisense strand.

^c D, Asp; E, Glu; F, Phe; K, Lys; L, Leu; P, Pro; S, Ser; V, Val; Y, Tyr; Wt, wild type.




FIG. 2. The probe spot layout of the microarray layout for *S. aureus* genotyping. Spot numbers correspond to the probe numbers in Table 2. The probes, which identify point mutations, are surrounded with squares. Spots enclosed by thick lines were used to detect the Wt (numbers 1, 3, 5, 7, 9, 11, 13, 19, 25, 27, 29, and 33), while those enclosed by thin lines were used to detect the mutants.

PCR product (35 μ l) was mixed with 15 μ l of 20 \times standard saline phosphate EDTA (SSPE) at the test site of the microarray, which was preheated to 50°C, and hybridization was initiated immediately. In flowthrough hybridization, the liquid flow rate was 25 μ l/s for 30 cycles (totaling approximately 5 min) at 50°C. To optimize the SBH analysis, kinetic analysis of the microarrays was performed with postwashing steps using 50 μ l of SSPE buffers at five different concentrations: 6 \times (960 mM NaCl), 3 \times (480 mM NaCl), 1 \times (160 mM NaCl), 0.5 \times (80 mM NaCl), and 0.05 \times (8 mM NaCl). All postwashing steps were performed for five pumping cycles. Images of the array were then captured automatically and analyzed using the image analysis software of the FD10 system. To confirm the reproducibility of this microarray system, duplicate experiments were carried out for the samples, each one of which was amplified and hybridized on different days.

RESULTS

Multiplex PCR. Multiplex PCR was designed to amplify three regions, including the *mecA* gene and the QRDRs of the *gyrAB* and *grlAB* genes (Table 1). Each multiplex PCR product was amplified as a single band of the predicted size for the *gyrAB*, *grlAB*, and *mecA* genes (1,255, 1,457, and 163 bp, respectively). The amounts of DNA fragments amplified by 40 cycles of multiplex PCR were sufficient for microarray analysis.

Microarray analysis. PCR products from the *mecA* gene were hybridized efficiently with both sense and antisense strand probes in all isolates. On the other hand, those from the *gyrAB* and *grlAB* genes were hybridized with either sense or antisense strand probes. In all isolates, hybridization signals for Pro451(Wt) and Pro451Ser in GrIB were observed only in an

antisense strand probe, while signals for the following in GrIA were observed only in a sense strand probe: Tyr47(Wt) and Tyr47(Si) (silent mutation); Asp79(Wt)Ser80(Wt), Asp79(Wt)Ser80Tyr, Asp79(Wt)Ser80Phe, Asp79ValSer80(Wt), Asp79ValSer80Tyr, and Asp79ValSer80Phe; and Glu84(Wt) and Glu84Lys in GrIA (Fig. 3).

To optimize the assay conditions for each target/probe on the array, the fluorescence signal detection step, i.e., the postwashing step, was performed at five different sodium chloride concentrations. Images of the fluorescence signals were captured kinetically, and quantitative values for these signals were calculated by the FD10 system in MRSA HU2000-62S, -64, -86S, and -129 and in *S. aureus* RN4220. Kinetic data for MRSA HU2000-62S are shown in Fig. 4. Although nonspecific signals were observed in all antisense probes for Glu84 and Asp79Ser80 in GrIA in the range of 1 \times to 6 \times SSPE, specific signals were detected at 0.5 \times SSPE. All sense or antisense probes for Ser84Ser85 in GyrA, Tyr47 in GrIA, and Pro451 in GrIB were detected at 6 \times SSPE. No signal was detected at 0.05 \times SSPE. These kinetic analyses showed the recognition of significant hybridization signals for all probes except those for Glu88(Wt) and Glu88Lys in GyrA with two postwashing conditions: 0.5 \times and 6 \times SSPE. In both 0.5 \times and 6 \times SSPE, PCR products of the *grlAB* genes were cross-hybridized with the probe for Glu88(Wt) in GyrA (data not shown). The Tyr47(Si) genotype was preserved in all isolates of MRSA, according to the DNA sequencing analysis. The intensities of the cross-hybridized signals were corrected by considering the signal intensities as ratios relative to the signal intensity of Tyr47(Si). The signal intensity cross-hybridized with the probe for Glu88(Wt) was found to be 0.5 ± 0.1 times that for Tyr47(Si) in MRSA HU2000-62S, -64, -86S, and -129. Cross-hybridization signals were then corrected using the formula $T_s = O_{Glu} - Cf \cdot O_{Tyr}$ [T_s , true signal intensity for Glu88(Wt); O_{Glu} , observed signal intensity for Glu88(Wt); Cf , correction factor of 0.5; O_{Tyr} , observed signal intensity for Tyr47(Si)]. Alignment of the DNA sequences of the probe for Glu88(Wt) in GyrA and those of the PCR product for the *grlAB* gene showed that continuous homology with 11 bp was contained in the centers of the probes. Cross-hybridization occurred in all *S. aureus* strains. The genetic relationship between GyrA and GrIA is very close; that is,




FIG. 3. Hybridization image in MRSA HU2000-228. Areas surrounded by squares indicate spots of probe sets for the detection of each specific point mutation on the microarray. Square 1, Pro451 in GrIB was observed in antisense strand probes; square 2, Tyr47 in GrIA in sense strand probes; square 3, Glu84 in GrIA in sense strand probes; square 4, Asp79Ser80 in GrIA in sense strand probes. The illustration to the right indicates the region of each probe in the *grlAB* gene and the strand for the detection of point mutations in the *grlAB* gene.




FIG. 4. Kinetic fluorescence signal intensities in MRSA HU2000-62S. (A) Ser84Ser85: Ser84(Wt)Ser85(Wt), TCATCT (□); Ser84(Wt)Ser85Pro, TCACCT (■); Ser84LeuSer85(Wt), TTATCT (○); Ser84LeuSer85Pro, TTACCT (●). (B) Asp79Ser80: Asp79(Wt)Ser80(Wt), GATTC (□); Asp79(Wt)Ser80Tyr, GACTAC (○); Asp79(Wt)Ser80Phe, GACTTC (●); Asp79ValSer80(Wt), GTCTCC (▲); Asp79ValSer80Tyr, GTCTAC (△); Asp79ValSer80Phe, GTCTCC (■). (C) Glu84: Glu84(Wt), GAA (○); Glu84Lys, AAA (●). Fluorescence signal intensities calculated from 0.05×-to-6× SSPE postwashing steps are shown. Duplicate experiments were carried out for each sample.

the amino acid residues from 71 to 92 in the QRDRs of GyrA are homologous to those from 67 to 96 in GrlA (approximately 80% amino acid homology). Ser84 and Glu88 in GyrA corresponded to Ser80 and Glu84, respectively, in GrlA. The similarities of these DNA sequences could account for the cross-hybridization observed in the SBH analysis. On the other hand, PCR products for the *grrAB* gene showed no cross-hybridization in any *S. aureus* strains by use of a probe for Glu88Lys containing 8 bp of continuous homology (data not shown). The signal at Glu88 was corrected using image analysis software to determine the genotype exactly.

To examine the assay sensitivity and reproducibility around the limit concentration for genotyping, hybridization experiments using three diluted multiplex PCR products (1/10, 1/50, and 1/100) derived from two isolates were performed. Diluted samples were hybridized to the PamChip microarray in triplicate. In total, 18 arrays (test sites) of six microarrays were used. Hybridization signals were clear and detectable on the microarrays in all diluted samples (Fig. 5), whereas in the samples diluted to 1/50 and 1/100, PCR-amplified fragment bands could not be detected with a LabChip 7500 kit. The concentrations of amplified fragments of the *gyrAB* and *grrAB* genes in 1/100-diluted samples of MRSA HU2000-62S and -64 were esti-

mated as 11.9 to 31.5 pM and 14.0 to 51.0 pM, respectively. The signal intensity ratios between perfect-match probe and mismatch probes always showed similar profiles (Fig. 5).

Evaluation of clinical isolates. Microarray analysis was performed under both 0.5× SSPE and 6× SSPE postwashing conditions in 24 MRSA isolates and 3 *S. aureus* isolates in duplicate. In the RDBH analysis for the *mecA* gene, a signal intensity at 0.5× SSPE above a predetermined threshold (>3,000 with a 0.2-s shutter speed) was considered positive for the presence of the DNA sequence. All MRSA isolates showed positive signals for the *mecA* gene, and all MSSA isolate signals were negative. These results perfectly corresponded to those obtained by the conventional PCR method (Table 3). In the SBH analysis of the QRDRs, the probe that produced the strongest signal intensity among the probe sets for the Wt and the mutants was judged a perfect-match sequence. Point mutations in the QRDRs determined by the PamChip microarray system corresponded to those determined by the DNA sequencer and were associated with amino acid substitutions such as Ser84Leu, Ser85Pro, and Glu88Lys in GyrA; Ser80Phe, Ser80Tyr, and Glu84Lys in GrlA; and Pro451Ser in GrlB (Table 3). Double-point mutations such as those corresponding to Ser84Leu and Ser85Pro in GyrA were detected using only a single probe. After calculation of the cross-hybridization signal




FIG. 5. Sensitivity and reproducibility of the microarray assay around the limit concentration for mutation detection. Representative results obtained with three diluted multiplex PCR products from two isolates are shown. (A) Asp79Ser80 in MRSA HU2000-62S. (B) Asp79Ser80 in MRSA HU2000-64. Abbreviations for GrlA products: Wt, wild type; DS, Asp79(Wt)Ser80(Wt); DY, Asp79(Wt)Ser80Tyr; DF, Asp79(Wt)Ser80Phe; VS, Asp79ValSer80(Wt); VY, Asp79ValSer80Tyr; VF, Asp79ValSer80Phe. Dilution series of PCR products are 1/10 (\square), 1/50 (\triangle), and 1/100 (\diamond). The percentages of the fluorescence signal intensities of genotypes related to Asp79Ser80 at $0.5\times$ SSPE were calculated by the following formula: observed signal on probe/highest signal in the same target probes \times 100.

of Glu88(Wt) in GyrA, the genotype corresponding to Glu88Lys was identified in seven isolates of MRSA HU2000-86S, -91S, -92, -135, -177, -199, and -214. In all isolates of *S. aureus* examined, the microarray system reliably identified the point mutation and the presence of the *mecA* gene (Table 3).

DISCUSSION

In this study we evaluated a novel three-dimensional microarray (PamChip microarray) system for the rapid and easy detection of levofloxacin resistance and the *mecA* gene in *S. aureus*. The microarray was designed to determine eight point mutation sites in the QRDRs of the *gyrAB* and *grlAB* genes and to detect the DNA sequence of the *mecA* gene simultaneously. All clinical isolate results of SBH and RDBH analysis with the microarray system corresponded to those of conventional DNA sequencing or PCR methods. Notably, double-point mutations, located near one another in the probes, could be analyzed by the microarray system. It could be difficult to detect them simultaneously using the TaqMan or Invader assay methods (2, 32).

Diluted PCR products in three different concentrations (1/10, 1/50, and 1/100) were analyzed with the PamChip microarray. Similar fluorescence intensity ratios were shown between the perfect-match probe and mismatch probes at all concentrations, whereas signal intensities were not always consistent with the theoretical density ratio. These results indicated that reproducibility around the limit concentration for signal detection is almost satisfactory and suitable for our microarray analysis. Moreover, the limit concentration for the signal detection of this system was about 10 times greater than that of conventional PCR methods (less than several pM).

The number of clinical isolates was too small to discuss analytical sensitivity and specificity for the microarray assay exactly. In future, it will be necessary to test a large number of

isolates. Wang et al. (31) showed that 179 clinical isolates of levofloxacin-resistant MRSA in Japan each had one of the following genotype combinations: (i) Ser80Phe or Ser80Tyr in GyrA and Ser84Leu in GrlA, (ii) Ser80Phe or Ser80Tyr in GrlA and Glu88Lys in GyrA, and (iii) Glu84Lys in GrlA and Ser84Leu in GyrA. All of these genotypes of MRSA were included in this study. Our microarray system could have a possibility for a high level of analytical sensitivity in the detection of the levofloxacin resistance of MRSA isolates in Japan.

PCR primers for the amplification of the *mecA* gene, previously described by Mehrotra et al. (18), were used for our study as components of multiplex PCR or conventional PCR. In this previous report, they showed that the specificity of *mecA* gene detection using the PCR primers was 94% (18/19) for MRSA isolates. In *mecA* gene detection, the results with our microarray analysis corresponded to those obtained by conventional PCR (24/24). The specificity seemed to be almost equivalent to that of our microarray analysis.

Real-time PCR using the evaluation of melting curve analyses for point mutations is easy, fast, less costly, and comprehensive (5, 14); however, it could have artifacts due to the melting curve profile. This method suits mutation analysis of a single amplicon or of a few amplicons. Microarray analysis using specific hybridization can simultaneously analyze multiple mutation sites in combination with a multiplex PCR technique. As other several-point mutations in the QRDRs of the *gyrAB* and *grlAB* genes have been reported previously (8, 22, 23), the addition of probes to detect these mutations will make our system more comprehensive. Moreover, our microarray assay system has advantages in terms of the optimization of hybridization conditions for each target/probe within a single array.

In kinetic analysis, the stringency of the postwashing conditions was increased by decreasing the sodium chloride concentrations. To detect the point mutations associated with Glu84

TABLE 3. Results of the genotyping analysis for *S. aureus* by PamChip microarray

Strain	Mutation in ^a :						<i>mecA</i> result ^b
	<i>grlA</i> codon(s) (product[s]):			<i>griB</i> codon 451 (P) (product)	<i>gyrA</i> codon(s) (product[s]):		
	47 (Y)	79 (D) 80 (S)	84 (E)		84 (S) 85 (S)	88 (E)	
MRSA							
HU2000-							
62S	TAT(Si)	GAC(Wt)TTC(F)	AAA(K)	CCA(Wt)	TTA(L)CCT(P)	GAA(Wt)	P
63S	TAT(Si)	GAC(Wt)TAC(Y)	AAA(K)	CCA(Wt)	TTA(L)TCT(Wt)	GAA(Wt)	P
64	TAT(Si)	GAC(Wt)TAC(Y)	GAA(Wt)	CCA(Wt)	TTA(L)TCT(Wt)	GAA(Wt)	P
86S	TAT(Si)	GAC(Wt)TTC(F)	GAA(Wt)	CCA(Wt)	TCA(Wt)TCT(Wt)	AAC(K)	P
91S	TAT(Si)	GAC(Wt)TTC(F)	GAA(Wt)	CCA(Wt)	TCA(Wt)TCT(Wt)	AAC(K)	P
92	TAT(Si)	GAC(Wt)TTC(F)	GAA(Wt)	CCA(Wt)	TCA(Wt)TCT(Wt)	AAC(K)	P
120	TAT(Si)	GAC(Wt)TAC(Y)	GAA(Wt)	CCA(Wt)	TTA(L)TCT(Wt)	GAA(Wt)	P
129	TAT(Si)	GAC(Wt)TTC(F)	GAA(Wt)	TCA(S)	TTA(L)TCT(Wt)	GAA(Wt)	P
133	TAT(Si)	GAC(Wt)TAC(Y)	GAA(Wt)	CCA(Wt)	TTA(L)TCT(Wt)	GAA(Wt)	P
134	TAT(Si)	GAC(Wt)TAC(Y)	GAA(Wt)	CCA(Wt)	TTA(L)TCT(Wt)	GAA(Wt)	P
135	TAT(Si)	GAC(Wt)TTC(F)	GAA(Wt)	CCA(Wt)	TCA(Wt)TCT(Wt)	AAC(K)	P
136	TAT(Si)	GAC(Wt)TAC(Y)	GAA(Wt)	CCA(Wt)	TTA(L)TCT(Wt)	GAA(Wt)	P
156	TAT(Si)	GAC(Wt)TTC(F)	GAA(Wt)	TCA(S)	TTA(L)TCT(Wt)	GAA(Wt)	P
177	TAT(Si)	GAC(Wt)TTC(F)	GAA(Wt)	CCA(Wt)	TCA(Wt)TCT(Wt)	AAC(K)	P
178	TAT(Si)	GAC(Wt)TTC(F)	GAA(Wt)	TCA(S)	TTA(L)TCT(Wt)	GAA(Wt)	P
199	TAT(Si)	GAC(Wt)TTC(F)	GAA(Wt)	CCA(Wt)	TCA(Wt)TCT(Wt)	AAC(K)	P
214	TAT(Si)	GAC(Wt)TTC(F)	GAA(Wt)	CCA(Wt)	TCA(Wt)TCT(Wt)	AAC(K)	P
228	TAT(Si)	GAC(Wt)TTC(F)	GAA(Wt)	TCA(S)	TTA(L)TCT(Wt)	GAA(Wt)	P
240	TAT(Si)	GAC(Wt)TAC(Y)	AAA(K)	CCA(Wt)	TTA(L)TCT(Wt)	GAA(Wt)	P
SHH-							
41	TAT(Si)	GAC(Wt)TTC(F)	GAA(Wt)	TCA(S)	TTA(L)TCT(Wt)	GAA(Wt)	P
43	TAT(Si)	GAC(Wt)TAC(Y)	GAA(Wt)	CCA(Wt)	TTA(L)TCT(Wt)	GAA(Wt)	P
44	TAT(Si)	GAC(Wt)TTC(F)	GAA(Wt)	TCA(S)	TTA(L)TCT(Wt)	GAA(Wt)	P
45	TAT(Si)	GAC(Wt)TTC(F)	GAA(Wt)	TCA(S)	TTA(L)TCT(Wt)	GAA(Wt)	P
46	TAT(Si)	GAC(Wt)TAC(Y)	GAA(Wt)	CCA(Wt)	TTA(L)TCT(Wt)	GAA(Wt)	P
MSSA							
RN4220	TAT(Si)	GAC(Wt)TCC(Wt)	GAA(Wt)	CCA(Wt)	TCA(Wt)TCT(Wt)	GAA(Wt)	N
Taku	TAT(Si)	GAC(Wt)TCC(Wt)	GAA(Wt)	CCA(Wt)	TCA(Wt)TCT(Wt)	GAA(Wt)	N
NCTC8325	TAT(Si)	GAC(Wt)TCC(Wt)	GAA(Wt)	CCA(Wt)	TCA(Wt)TCT(Wt)	GAA(Wt)	N

^a D, Asp; E, Glu; F, Phe; K, Lys; L, Leu; P, Pro; S, Ser; Y, Tyr.

^b P, positive; N, negative.

and Asp79Ser80 in *GrlA*, the concentration of SSPE was reduced to 0.5× because of high T_m values. Specific signals for Pro451 in *GriB* were detected at 6× SSPE, while those for Glu84 in *GrlA* were detected at 0.5× SSPE, although the calculated T_m range of the probes for Pro451 in *GriB* was similar to that for Glu84 in *GrlA* (52 to 54°C). An accurate calculation of T_m values may be difficult for a probe with a mismatch site to the target DNA sequence. Accordingly, kinetic analysis is required under differing hybridization conditions, such as temperatures, or the use of multiple probes with different T_m values for a given point mutation may be required. Our results suggested that the PamChip microarray system was advantageous for the determination of specific hybridization conditions using kinetic analysis.

Hybridization steps were performed semiautomatically by the FD10 system. The total analysis time is within approximately 3.5 h: DNA extraction for 1 h by hand, PCR for 2 h, and automatic microarray analysis for 25 min (hybridization for 8 min, two washing steps for 12 min, and the data analysis step for 5 min). The PamChip microarray greatly reduces the time necessary for the hybridization analysis. Clinically, there is already a 24-h time addition if the process for microarray begins with the isolation of an organism from culture. It also

requires PCR amplification of the target region as in other genetic methods based on PCR. To reduce the total assay time for genotyping and contamination errors, the PCR step ideally should be omitted in future. In this study, to specifically amplify the target DNA sequences, multiplex PCR was performed using a minimum of three primer sets designed with the *gyrAB*, *griAB*, and *mecA* genes. Since the amounts of amplified products by multiplex PCR were less than those produced by single PCR in some isolates, 40 cycles were required for the stable multiplex amplification of DNA, and the products were used for microarray analysis.

Southern et al. (24) noted that short targets are better able to hybridize with oligonucleotide probes in a microarray than large targets are and stated that, ideally, targets and probes should have the same lengths. In our study, the combination of a 163-bp target for the *mecA* gene and 26 bases of specific probe resulted in hybridization that was efficient in comparison with that seen with a 1,255-bp target for the *gyrAB* gene or a 1,457-bp target for the *griAB* gene and their short specific probes (20 to 25 bases). Hybridization signals for the *gyrAB* and *griAB* targets were detected on either a sense or an anti-sense strand probe. Moreover, although the same target was used to detect the *grlA* and the *griB* genes, hybridization signals

for probes in the *grlA* gene were observed in the sense strand, and those for probes in the *grlB* gene were in the antisense strand (Fig. 3). This phenomenon suggests that the hybridization efficiencies for sense and antisense strand probes differ. This is in agreement with previous reports that the difference in signal intensities may depend on the secondary structures of probes and targets (3, 16, 20, 24). Therefore, the secondary structures of probes and targets are one of the important factors in microarray analysis.

We have not yet performed an assay using raw specimens. If plural genotypes of *S. aureus* are included in raw specimens, it may be difficult to detect them. Further, such evaluations with raw specimens are needed.

In conclusion, the unique features of the three-dimensional microarray (PamChip microarray) system provided a rapid, specific, easy, and reproducible detection of levofloxacin resistance and *mecA* resistance in *S. aureus* simultaneously. Flexibility for the optimization of hybridization conditions for each target nucleic acid and probe could be suitable for multiplex detection on the array. Our results suggest that this microarray technique has the potential for application in clinical microbiology laboratories in the future.

ACKNOWLEDGMENT

This study was supported by a Grant-in-Aid for Scientific Research (17790353) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

REFERENCES

- Centers for Disease Control and Prevention. 1999. Four pediatric deaths from community-acquired methicillin-resistant *Staphylococcus aureus*—Minnesota and North Dakota 1997–1999. *Morb. Mortal. Wkly. Rep.* **48**:707–710.
- Cooksey, R. C., B. P. Holloway, M. C. Oldenburg, S. Listenbee, and C. W. Miller. 2000. Evaluation of the Invader assay, a linear signal amplification method, for identification of mutations associated with resistance to rifampin and isoniazid in *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* **44**:1296–1301.
- Dong, F., H. T. Allawi, T. Anderson, B. P. Neri, and V. I. Lyamichev. 2001. Secondary structure prediction and structure-specific sequence analysis of single-stranded DNA. *Nucleic Acids Res.* **29**:3248–3257.
- Drica, K., and X. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. *Microbiol. Mol. Biol. Rev.* **61**:377–392.
- Fang, H., and G. Hedin. 2003. Rapid screening and identification of methicillin-resistant *Staphylococcus aureus* from clinical samples by selective-broth and real-time PCR assay. *J. Clin. Microbiol.* **41**:2894–2899.
- Ferrero, L., B. Cameron, B. Manse, D. Lagneaux, J. Crouzet, A. Famechon, and F. Blanche. 1994. Cloning and primary structure of *Staphylococcus aureus* DNA topoisomerase IV: a primary target of fluoroquinolones. *Mol. Microbiol.* **13**:641–653.
- Ferrero, L., B. Cameron, and J. Crouzet. 1995. Analysis of *gyrA* and *grrA* mutations in stepwise-selected ciprofloxacin-resistant mutants of *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **39**:1554–1558.
- Hannachi-M'Zali, F., J. E. Ambler, C. F. Taylor, and P. M. Hawkey. 2002. Examination of single and multiple mutations involved in resistance to quinolones in *Staphylococcus aureus* by a combination of PCR and denaturing high-performance liquid chromatography (DHPLC). *J. Antimicrob. Chemother.* **50**:649–655.
- Hokaiwado, N., M. Asamoto, K. Tsujimura, T. Hirota, T. Ichihara, T. Satoh, and T. Shirai. 2004. Rapid analysis of gene expression changes caused by liver carcinogens and chemopreventive agents using a newly developed three-dimensional microarray system. *Cancer Sci.* **95**:123–130.
- Horii, T., K. Yokoyama, S. Barua, T. Odagiri, N. Futamura, T. Hasegawa, and M. Ohta. 2000. The staphylokinase gene is located in the structural gene encoding *N*-acetylmuramyl-L-alanine amidase in methicillin-resistant *Staphylococcus aureus*. *FEMS Microbiol. Lett.* **185**:221–224.
- Horii, T., Y. Suzuki, A. Monji, M. Morita, H. Muramatsu, Y. Kondo, M. Doi, A. Takeshita, T. Kanno, and M. Maekawa. 2003. Detection of mutations in quinolone resistance-determining regions in levofloxacin- and methicillin-resistant *Staphylococcus aureus*: effects of the mutations on fluoroquinolone MICs. *Diagn. Microbiol. Infect. Dis.* **46**:139–145.
- Ida, T., R. Okamoto, C. Shimauchi, T. Okubo, A. Kuga, and M. Inoue. 2001. Identification of aminoglycoside-modifying enzymes by susceptibility testing: epidemiology of methicillin-resistant *Staphylococcus aureus* in Japan. *J. Clin. Microbiol.* **39**:3115–3121.
- Ito, H., H. Yoshida, M. Bogaki-Shonai, T. Niga, H. Hattori, and S. Nakamura. 1994. Quinolone resistance mutations in the DNA gyrase *gyrA* and *gyrB* genes of *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **38**:2014–2023.
- Lapierre, P., A. Huletsky, V. Fortin, F. J. Picard, P. H. Roy, M. Ouellette, and M. G. Bergeron. 2003. Real-time PCR assay for detection of fluoroquinolone resistance associated with *grrA* mutations in *Staphylococcus aureus*. *J. Clin. Microbiol.* **41**:3246–3251.
- Lowy, F. D. 2003. Antimicrobial resistance: the example of *Staphylococcus aureus*. *J. Clin. Investig.* **111**:1265–1273.
- Luebke, K. J., R. P. Balog, and H. R. Garner. 2003. Prioritized selection of oligodeoxynucleotide probes for efficient hybridization to RNA transcripts. *Nucleic Acids Res.* **31**:750–758.
- Maekawa, M., T. Nagaoka, T. Taniguchi, H. Higashi, H. Sugimura, K. Sugano, H. Yonekawa, T. Satoh, T. Horii, N. Shirai, A. Takeshita, and T. Kanno. 2004. Three-dimensional microarray compared with PCR-single-strand conformation polymorphism analysis and DNA sequencing for mutation analysis of *K-ras* codons 12 and 13. *Clin. Chem.* **50**:1322–1327.
- Mehrotra, M., G. Wang, and W. M. Johnson. 2000. Multiplex PCR for detection of genes for *Staphylococcus aureus* enterotoxins, exfoliative toxins, toxic shock syndrome toxin 1, and methicillin resistance. *J. Clin. Microbiol.* **38**:1032–1035.
- Murakami, K., W. Minamide, K. Wada, E. Nakamura, H. Teraoka, and S. Watanabe. 1991. Identification of methicillin-resistant strains of staphylococci by polymerase chain reaction. *J. Clin. Microbiol.* **29**:2240–2244.
- Peplies, J., F. O. Glockner, and R. Amann. 2003. Optimization strategies for DNA microarray-based detection of bacteria with 16S rRNA-targeting oligonucleotide probes. *Appl. Environ. Microbiol.* **69**:1397–1407.
- Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. *Molecular cloning: a laboratory manual*, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
- Schmitz, F. J., B. Hofmann, B. Hansen, S. Scheuring, M. Luckefahr, M. Klootwijk, J. Verhoef, A. Fluit, H. P. Heinz, K. Kohrer, and M. E. Jones. 1998. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12–8039) MICs and mutations in *grrA*, *grrB*, *gyrA* and *gyrB* in 116 unrelated clinical isolates of *Staphylococcus aureus*. *J. Antimicrob. Chemother.* **41**:481–484.
- Schmitz, F. J., M. E. Jones, B. Hofmann, B. Hansen, S. Scheuring, M. Luckefahr, A. Fluit, J. Verhoef, U. Hadding, H. P. Heinz, and K. Kohrer. 1998. Characterization of *grrA*, *grrB*, *gyrA*, and *gyrB* mutations in 116 unrelated isolates of *Staphylococcus aureus* and effects of mutations on ciprofloxacin MIC. *Antimicrob. Agents Chemother.* **42**:1249–1252.
- Southern, E., K. Mir, and M. Shchepinov. 1999. Molecular interactions on microarrays. *Nat. Genet.* **21**:5–9.
- Stromenger, B., C. Kettlitz, G. Werner, and W. Witte. 2003. Multiplex PCR assay for simultaneous detection of nine clinically relevant antibiotic resistance genes in *Staphylococcus aureus*. *J. Clin. Microbiol.* **41**:4089–4094.
- Takahashi, H., T. Kikuchi, S. Shoji, S. Fujimura, A. B. Lutfor, Y. Tokue, T. Nukiwa, and A. Watanabe. 1998. Characterization of *gyrA*, *gyrB*, *grrA* and *grrB* mutations in fluoroquinolone-resistant clinical isolates of *Staphylococcus aureus*. *J. Antimicrob. Chemother.* **41**:49–57.
- Tanaka, M., Y. X. Zhang, H. Ishida, T. Akasaka, K. Sato, and I. Hayakawa. 1995. Mechanisms of 4-quinolone resistance in quinolone-resistant and methicillin-resistant *Staphylococcus aureus* isolates from Japan and China. *J. Med. Microbiol.* **42**:214–219.
- Tokuem, Y., K. Sugano, D. Saito, T. Noda, H. Ohkura, Y. Shimosato, and T. Sekiya. 1994. Detection of novel mutations in the *gyrA* gene of *Staphylococcus aureus* by nonradioisotopic single-strand conformation polymorphism analysis and direct DNA sequencing. *Antimicrob. Agents Chemother.* **38**:428–431.
- Utsui, Y., and T. Yokota. 1985. Role of an altered penicillin-binding protein in methicillin- and cephem-resistant *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **28**:397–403.
- van Beuming, R., H. van Damme, P. Boender, N. Bastiaensen, A. Chan, and T. Kiebits. 2001. Fast and specific hybridization using flow-through microarrays on porous metal oxide. *Clin. Chem.* **47**:1931–1933.
- Wang, T., M. Tanaka, and K. Sato. 1998. Detection of *grrA* and *gyrA* mutations in 344 *Staphylococcus aureus* strains. *Antimicrob. Agents Chemother.* **42**:236–240.
- Wilson, D. L., S. R. Abner, T. C. Newman, L. S. Mansfield, and J. E. Linz. 2000. Identification of ciprofloxacin-resistant *Campylobacter jejuni* by use of a fluorogenic PCR assay. *J. Clin. Microbiol.* **38**:3971–3978.